Agile Therapeutics, Inc. provides revenue guidance for the year 2023. For the year, the company expects $25 million - $30 million in revenue largely due to Twirla.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.374 USD | -0.98% | -1.58% | -80.82% |
05-15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
03-28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
1st Jan change | Capi. | |
---|---|---|
-80.82% | 2.56M | |
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023